▶ 調査レポート

ビンカアルカロイド化合物のグローバル市場(~2027):ビンブラスチン、ビンクリスチン、ビンデシン、ビノレルビン

• 英文タイトル:Vinca Alkaloid Compounds Market Research Report by Product, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

Vinca Alkaloid Compounds Market Research Report by Product, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19「ビンカアルカロイド化合物のグローバル市場(~2027):ビンブラスチン、ビンクリスチン、ビンデシン、ビノレルビン」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2304E001
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、222ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:材料
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社発行の当市場調査レポートでは、2021年に97.55百万ドルであった世界のビンカアルカロイド化合物市場規模が、2022年に106.23百万ドルに達し、2027年には164.30百万ドルまでCAGR 9.07%で成長すると見込まれています。当レポートは、ビンカアルカロイド化合物の世界市場を多角的に調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別(ビンブラスチン、ビンクリスチン、ビンデシン、ビノレルビン)分析、エンドユーザー別(学術&研究機関、病院&医療提供者、製薬&バイオテクノロジー企業)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況など、以下の項目をまとめています。また、当書は、Accord Healthcare Limited、David Bull Laboratories (Pty) Ltd.、Eli Lilly and Company Limited、Fine Chemicals Corporation、Guangzhou Hanfang Pharmaceutical、Guangzhou Person Pharmaceutical、Hainan Vinca biological medicine technologyなどの企業情報を含んでいます。

・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界のビンカアルカロイド化合物市場規模:製品別
- ビンブラスチンの市場規模
- ビンクリスチンの市場規模
- ビンデシンの市場規模
- ビノレルビンの市場規模
・世界のビンカアルカロイド化合物市場規模:エンドユーザー別
- 学術&研究機関における市場規模
- 病院&医療提供者における市場規模
- 製薬&バイオテクノロジー企業における市場規模
・世界のビンカアルカロイド化合物市場規模:地域別
- 南北アメリカのビンカアルカロイド化合物市場規模
アメリカのビンカアルカロイド化合物市場規模
カナダのビンカアルカロイド化合物市場規模
ブラジルのビンカアルカロイド化合物市場規模

- アジア太平洋のビンカアルカロイド化合物市場規模
日本のビンカアルカロイド化合物市場規模
中国のビンカアルカロイド化合物市場規模
インドのビンカアルカロイド化合物市場規模
韓国のビンカアルカロイド化合物市場規模
台湾のビンカアルカロイド化合物市場規模

- ヨーロッパ/中東/アフリカのビンカアルカロイド化合物市場規模
イギリスのビンカアルカロイド化合物市場規模
ドイツのビンカアルカロイド化合物市場規模
フランスのビンカアルカロイド化合物市場規模
ロシアのビンカアルカロイド化合物市場規模

- その他地域のビンカアルカロイド化合物市場規模

・競争状況
・企業情報

The Global Vinca Alkaloid Compounds Market size was estimated at USD 97.55 million in 2021 and expected to reach USD 106.23 million in 2022, and is projected to grow at a CAGR 9.07% to reach USD 164.30 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Vinca Alkaloid Compounds to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market was studied across Vinblastine, Vincristine, Vindesine, and Vinorelbine.

Based on End User, the market was studied across Academic & Research Institutes, Hospitals & Care Providers, and Pharmaceutical & Biotechnology Companies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Vinca Alkaloid Compounds market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Vinca Alkaloid Compounds Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Vinca Alkaloid Compounds Market, including Accord Healthcare Limited, David Bull Laboratories (Pty) Ltd., Eli Lilly and Company Limited, Fine Chemicals Corporation, Guangzhou Hanfang Pharmaceutical, Guangzhou Person Pharmaceutical, Hainan Vinca biological medicine technology, Hainan Yueyang Biotechnology, Hansoh, Hospira, Inc., Hubei Honch Pharmaceutical, Min Sheng, Minakem SAS, Pfizer Inc., Pierre Fabre S.A., Talon Therapeutics, Inc., Teva Pharmaceutical Industries Limited, Uman Pharma, Vinkem, and Zhendong Group.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Vinca Alkaloid Compounds Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Vinca Alkaloid Compounds Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Vinca Alkaloid Compounds Market?
4. What is the competitive strategic window for opportunities in the Global Vinca Alkaloid Compounds Market?
5. What are the technology trends and regulatory frameworks in the Global Vinca Alkaloid Compounds Market?
6. What is the market share of the leading vendors in the Global Vinca Alkaloid Compounds Market?
7. What modes and strategic moves are considered suitable for entering the Global Vinca Alkaloid Compounds Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of elderly population coupled with rising chronic diseases such as cancer worldwide
5.1.1.2. Changing consumer lifestyle resulting in increasing diabetes, high blood pressure and other conditions
5.1.1.3. Increasing healthcare expenditure in developed and developing economies
5.1.2. Restraints
5.1.2.1. Chances of side effects in patients such as constipation, mucositis, and alopecia
5.1.3. Opportunities
5.1.3.1. Rising research and development to explore the diverse applications of vinca alkoid compounds
5.1.3.2. Growing development of drug delivery systems and combination therapies for vinca alkoid compounds
5.1.4. Challenges
5.1.4.1. Stringent regulatory mandates for drug approval
5.2. Cumulative Impact of COVID-19

6. Vinca Alkaloid Compounds Market, by Product
6.1. Introduction
6.2. Vinblastine
6.3. Vincristine
6.4. Vindesine
6.5. Vinorelbine

7. Vinca Alkaloid Compounds Market, by End User
7.1. Introduction
7.2. Academic & Research Institutes
7.3. Hospitals & Care Providers
7.4. Pharmaceutical & Biotechnology Companies

8. Americas Vinca Alkaloid Compounds Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Vinca Alkaloid Compounds Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Vinca Alkaloid Compounds Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Accord Healthcare Limited
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. David Bull Laboratories (Pty) Ltd.
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Eli Lilly and Company Limited
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Fine Chemicals Corporation
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Guangzhou Hanfang Pharmaceutical
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. Guangzhou Person Pharmaceutical
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Hainan Vinca biological medicine technology
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Hainan Yueyang Biotechnology
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Hansoh
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Hospira, Inc.
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. Hubei Honch Pharmaceutical
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Min Sheng
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Minakem SAS
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Pfizer Inc.
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. Pierre Fabre S.A.
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. Talon Therapeutics, Inc.
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Teva Pharmaceutical Industries Limited
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. Uman Pharma
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. Vinkem
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Zhendong Group
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing